Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 20/20 | 0.72 |
| ▸ | IKBKE | Q14164 | 12/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | NPC1 | O15118 | 1/20 | 0.72 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.72 |
| ▸ | TTR | P02766 | 1/20 | 0.72 |
| ▸ | GAA | P10253 | 1/20 | 0.72 |
| ▸ | PKM | P14618 | 1/20 | 0.72 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.72 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.72 |
| ▸ | RAB9A | P51151 | 1/20 | 0.72 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.72 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.72 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2908309 | 0.99 | TBK1 (0.71) | TBK1IKBKEKDM4ENPC1ABCC4 | |
| SCHEMBL2908311 | 0.99 | TBK1 (0.71) | TBK1IKBKEKDM4ENPC1ABCC4 | |
| SCHEMBL2908306 | 0.89 | TBK1 (0.57) | TBK1IKBKEKDM4ENPC1ABCC4 | |
| SCHEMBL11102044 | 0.86 | TBK1 (0.56) | TBK1IKBKEKDM4ENPC1ABCC4 | |
| SCHEMBL11358113 | 0.85 | TBK1 (0.53) | TBK1IKBKEKDM4ENPC1ABCC4 | |
| SCHEMBL2904833 | 0.84 | KDM4E (0.56) | TBK1IKBKEKDM4ENPC1ABCC4 | |
| SCHEMBL11096162 | 0.84 | TBK1 (0.54) | TBK1IKBKEKDM4ENPC1ABCC4 | |
| Amlexanox SCHEMBL29642 | 0.84 | TBK1 (1.00) | TBK1IKBKEKDM4ENPC1ABCC4 | |
| Amlexanox SCHEMBL5058549 | 0.84 | TBK1 (1.00) | TBK1IKBKEKDM4ENPC1ABCC4 | |
| Amlexanox SCHEMBL29381739 | 0.84 | TBK1 (1.00) | TBK1IKBKEKDM4ENPC1ABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1968981-B1 | AZAXANTHONES AND USE THEREOF FOR TREATING TUMORS | SUPRATEK PHARMA INC (CA) | 2010-08-18 | — | — | EP | claimed |
| US-7772255-B2 | Method of treating tumors with azaxanthones | SUPRATEK PHARMA, INC. (CA) | 2010-08-10 | — | — | US | claimed |
| US-20090042923-A1 | Method of Treating Tumors with Azaxanthones | SEMOV ALEXANDRE | 2009-02-12 | — | — | US | claimed |
| US-20070135473-A1 | Method of treating tumors with azaxanthones | SUPRATEK PHARMA, INC. | 2007-06-14 | — | — | US | claimed |
| US-4143042-A | ANTIALLERGENS, BRONCHODILATOR AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1979-03-06 | — | — | US | claimed |
| US-10590142-B2 | Deuterated amlexanox | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-03-17 | — | — | US | disclosed |
| EP-2991647-B1 | DEUTERATED AMLEXANOX WITH IMPROVED METABOLIC STABILITY | UNIV MICHIGAN REGENTS (US) | 2019-04-24 | — | — | EP | disclosed |
| US-10245255-B2 | Compositions and methods for the treatment of obesity and related disorders | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-04-02 | — | — | US | disclosed |
| US-9944652-B2 | Deuterated amlexanox | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-04-17 | — | — | US | disclosed |
| EP-2675275-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OBESITY AND RELATED DISORDERS | UNIV MICHIGAN REGENTS (US) | 2017-12-20 | — | — | EP | disclosed |
| US-20160251366-A1 | DEUTERATED AMLEXANOX | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2016-09-01 | — | — | US | disclosed |
| US-9365581-B2 | Deuterated amlexanox | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-06-14 | — | — | US | disclosed |
| US-20140329848-A1 | DEUTERATED AMLEXANOX | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-11-06 | — | — | US | disclosed |
| EP-2675275-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OBESITY AND RELATED DISORDERS | The Regents Of The University Of Michigan (US) | 2013-12-25 | — | — | EP | disclosed |
| WO-2012112558-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OBESITY AND RELATED DISORDERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-08-23 | — | — | WO | disclosed |
| US-20120208836-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OBESITY AND RELATED DISORDERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-08-16 | — | — | US | disclosed |
| EP-1968981-B1 | AZAXANTHONES AND USE THEREOF FOR TREATING TUMORS | SUPRATEK PHARMA INC (CA) | 2010-08-18 | — | — | EP | disclosed |
| US-7772255-B2 | Method of treating tumors with azaxanthones | SUPRATEK PHARMA, INC. (CA) | 2010-08-10 | — | — | US | disclosed |
| US-20090042923-A1 | Method of Treating Tumors with Azaxanthones | SEMOV ALEXANDRE | 2009-02-12 | — | — | US | disclosed |
| US-20070135473-A1 | Method of treating tumors with azaxanthones | SUPRATEK PHARMA, INC. | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590142-B2 | Deuterated amlexanox | DDX3X, DHX30, HAX1 | TBK1 3563/4885IKBKE 3768/4885KDM4E 1241/4885 |
| US-20070135473-A1 | Method of treating tumors with azaxanthones | S100A4, S100B, S100P | TBK1 2135/4885IKBKE 1437/4885KDM4E 1501/4885 |
| US-20140329848-A1 | DEUTERATED AMLEXANOX | DDX3X, DHX30, HAX1 | TBK1 3563/4885IKBKE 3768/4885KDM4E 1241/4885 |
| US-20160251366-A1 | DEUTERATED AMLEXANOX | DDX3X, DHX30, HAX1 | TBK1 3563/4885IKBKE 3768/4885KDM4E 1241/4885 |
| US-20120208836-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OBESITY AND RELATED DISORDERS | GPR119, LIPC, FABP4 | TBK1 2581/4885IKBKE 994/4885KDM4E 741/4885 |
| US-10245255-B2 | Compositions and methods for the treatment of obesity and related disorders | GPR119, LIPC, FABP4 | TBK1 2581/4885IKBKE 994/4885KDM4E 741/4885 |
| US-20090042923-A1 | Method of Treating Tumors with Azaxanthones | S100A4, S100P, S100B | TBK1 2247/4885IKBKE 1422/4885KDM4E 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.